Takeda’s Novel TTP Drug Moves Towards First Filing
Based On 'Totality' Of Data
New Phase III results set stage for a potential US submission in high-need indication of congenital thrombotic thrombocytopenic purpura in the next few months if company sticks to initial development plans.
